Jupiter Neurosciences (JUNS)
Develops CNS drug candidates and sells Nugevia longevity supplements.
Something off on this page? Send us feedback.
Develops investigational CNS medicines around a micellar-resveratrol platform and sells Nugevia nutritional supplements online. Revenue currently comes from supplements, while drug commercialization depends on clinical progress, regulatory approval, and licensed Aquanova technology.
Develops CNS drug candidates around JOTROL, a micellar resveratrol formulation used in JNS115, an exploratory Parkinson's study, while holding U.S. rights to the separate ALA-002 MDMA-based candidate. Potential follow-on JOTROL programs include mild cognitive impairment, early Alzheimer's disease and several rare diseases.
Also sells Nugevia supplements—GLO, MND and PWR—through U.S. direct-to-consumer e-commerce. Liquid ingredients are prepared by Aquanova in Germany, then encapsulated in California and shipped to consumers; European, Middle Eastern and Southeast Asian expansion remains planned.
Operates primarily as a virtual organization, with a small internal team coordinating strategy and regulatory work while outside partners conduct much of R&D, clinical operations and manufacturing. No drug candidate has FDA marketing approval, and both business segments depend on Aquanova's exclusive license, formulation technology and initial manufacturing step.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.5M · Total debt $1.7M · Total assets $3.7M · Shareholders' equity −$366.0K
- Revenue
- $24.2K
- Operating income
- −$2.7M
- Net income
- −$2.3M
No dividends on record.
| Institutions | 2.17% | 16.7K shares | |
|---|---|---|---|
| 13 holders · as of Jun 30, 2026 | |||
| Insiders | 31.03% | 239.0K shares | |
| 10 holders · as of Jul 13, 2026 | |||
| Strategic holders | 17.25% | 132.9K shares | |
| 1 holder · as of Sep 22, 2026 | |||
| Other | 49.55% | 381.5K shares | |
| remainder | |||
770.1K company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (770.1K in the company's Sep 23, 2026 report, 484.7K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Christer RosenInsiderdirector, 10 percent owner, officer: CEO and Chairman | 19.18% | 147,719 | filed Jul 3, 2025 |
PharmAla Biotech Holdings Inc.Strategic | 17.25% | 132,867 | filed Sep 22, 2026 |
Marshall A. HaywardInsiderdirector, officer: Chief Scientific Officer | 5.19% | 39,934 | filed Jul 13, 2026 |
Claes Robert WahlestedtInsider10 percent owner | 4.77% | 36,765 | filed Nov 13, 2024 |
Alexander Gustaf Erik RosenInsiderofficer: Chief Administrative Officer | 1.07% | 8,232 | filed Jul 13, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- AbbVie
Established levodopa infusions set the Parkinson's treatment standard.
- Amneal Pharmaceuticals
Oral levodopa brands contest Parkinson's treatment adoption.
- Eli Lilly
Approved Alzheimer's therapy serves patients with MCI.
- Niagen Bioscience
Tru Niagen targets DTC healthy-aging and cellular-energy buyers.
- Biogen
Leqembi co-commercialization creates a scaled MCI rival.
- Supernus Pharmaceuticals
Parkinson's medicines address dyskinesia and motor off episodes.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Jupiter Neurosciences | $2.95 | −1.08% | $1.4M | — | 2.0 | 22.3 | — |
| AbbVie | $264.81 | −0.15% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Amneal Pharmaceuticals | $18.99 | −2.60% | $6.23B | 40.0 | 19.1 | 2.0 | +9.9% |
| Eli Lilly | $1,154.84 | −1.31% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Niagen Bioscience | $3.07 | −0.65% | $246.1M | 16.6 | 27.4 | 1.9 | −4.3% |
| Biogen | $224.33 | −0.46% | $33.30B | 39.9 | 16.9 | 3.3 | +3.4% |
| Supernus Pharmaceuticals | $43.40 | −0.80% | $2.54B | — | 15.0 | 3.1 | +32.4% |
| Median | 39.9 | 18.2 | 3.2 | +10.0% |